The CDK4 and 6 inhibitor abemaciclib induces both epigenetic and immunogenic responses in preclinical models of Ewing's sarcoma

被引：0
|
作者：
Dowless, Michele [1 ]
Lowery, Caitlin [1 ]
Renschler, Matthew [1 ]
Blosser, Wayne [1 ]
Stephens, Jennifer [1 ]
Flack, Robert [1 ]
Credille, Kelly [1 ]
Chen, Mia [1 ]
Dorsey, Frank [1 ]
Sams, Lillian [1 ]
Ebert, Philip [1 ]
Olsen, Jonathan [1 ]
Shackleford, Terry [2 ]
Houghton, Peter [2 ]
Stancato, Louis [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] UT Hlth Sci Ctr, Greehey Childrens Canc Res Inst, San Antonio, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 19期
关键词：
D O I：
10.1158/1538-7445.PEDCA17-B43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B43
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
    Javier Martin-Broto
    Jeronimo Martinez-Garcia
    David S. Moura
    Andres Redondo
    Antonio Gutierrez
    Antonio Lopez-Pousa
    Javier Martinez-Trufero
    Isabel Sevilla
    Roberto Diaz-Beveridge
    Maria Pilar Solis-Hernandez
    Amancio Carnero
    Marco Perez
    David Marcilla
    Jesus Garcia-Foncillas
    Pablo Romero
    Javier Fernandez-Jara
    Daniel Lopez-Lopez
    Ivan Arribas
    Nadia Hindi
    Signal Transduction and Targeted Therapy, 8
  • [42] Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
    Sun, Chao-Yue
    Talukder, Milton
    Cao, Di
    Chen, Cun-Wu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [43] Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
    Martin-Broto, Javier
    Martinez-Garcia, Jeronimo
    Moura, David S.
    Redondo, Andres
    Gutierrez, Antonio
    Lopez-Pousa, Antonio
    Martinez-Trufero, Javier
    Sevilla, Isabel
    Diaz-Beveridge, Roberto
    Solis-Hernandez, Maria Pilar
    Carnero, Amancio
    Perez, Marco
    Marcilla, David
    Garcia-Foncillas, Jesus
    Romero, Pablo
    Fernandez-Jara, Javier
    Lopez-Lopez, Daniel
    Arribas, Ivan
    Hindi, Nadia
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [44] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [45] Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
    Gong, Xueqian
    Litchfield, Lacey M.
    Webster, Yue
    Chio, Li-Chun
    Wong, Swee Seong
    Stewart, Trent R.
    Dowless, Michele
    Dempsey, Jack
    Zeng, Yi
    Torres, Raquel
    Boehnke, Karsten
    Mur, Cecilia
    Marugan, Carlos
    Baquero, Carmen
    Yu, Chunping
    Bray, Steven M.
    Wulur, Isabella H.
    Bi, Chen
    Chu, Shaoyou
    Qian, Hui-Rong
    Iversen, Philip W.
    Merzoug, Farhana F.
    Ye, Xiang S.
    Reinhard, Christoph
    De Dios, Alfonso
    Du, Jian
    Caldwell, Charles W.
    Jose Lallena, Maria
    Beckmann, Richard P.
    Buchanan, Sean G.
    CANCER CELL, 2017, 32 (06) : 761 - +
  • [46] Preclinical development of a highly potent and selective dual inhibitor of CDK4/6 for the treatment of cancer
    Bantie, Laychiluh
    Tadesse, Solomon
    Likisa, Jimma
    Yu, Mingfeng
    Noll, Benjamin
    Albrecht, Hugo
    Milne, Robert
    Wang, Shudong
    CANCER RESEARCH, 2018, 78 (13)
  • [47] The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
    Schaer, David A.
    Beckmann, Richard P.
    Dempsey, Jack A.
    Huber, Lysiane
    Forest, Amelie
    Amaladas, Nelusha
    Li, Yanxia
    Wang, Ying Cindy
    Rasmussen, Erik R.
    Chin, Darin
    Capen, Andrew
    Carpenito, Carmine
    Staschke, Kirk A.
    Chung, Linda A.
    Litchfield, Lacey M.
    Merzoug, Farhana F.
    Gong, Xueqian
    Iversen, Philip W.
    Buchanan, Sean
    de Dios, Alfonso
    Novosiadly, Ruslan D.
    Kalos, Michael
    CELL REPORTS, 2018, 22 (11): : 2978 - 2994
  • [48] Igf1r mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor samples and in cellular models
    Wander, Seth A.
    Mao, Pingping
    Lloyd, Maxwell R.
    Johnson, Gabriela N.
    Kowalski, Kailey
    Nayar, Utthara
    Guenther, Lillian M.
    Stegmaier, Kimberly
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    CANCER RESEARCH, 2021, 81 (04)
  • [49] Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
    Bollard, Julien
    Miguela, Veronica
    de Galarreta, Marina Ruiz
    Venkatesh, Anu
    Bian, C. Billie
    Roberto, Mark P.
    Tovar, Victoria
    Sia, Daniela
    Molina-Sanchez, Pedro
    Nguyen, Christie B.
    Nakagawa, Shigeki
    Llovet, Josep M.
    Hoshida, Yujin
    Lujambio, Amaia
    GUT, 2017, 66 (07) : 1286 - 1296
  • [50] ABEMACICLIB, A SELECTIVE CDK4/6 INHIBITOR, RESTRICTS GROWTH OF PEDIATRIC GLIAL-LINEAGE TUMORS IN VITRO AND IN VIVO
    Liang, Muh-Lii
    Hsieh, Tsung-Han
    Wong, Tai-Tong
    NEURO-ONCOLOGY, 2020, 22 : 414 - 414
12345